Becton, Dickinson (BDX) and partner CerTest Biotec said on Monday their molecular polymerase chain reaction ((PCR)) assay for monkeypox virus was now commercially available…
WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.
The Closed-System Transfer Devices (CSTD) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement.
Major players in the aseptic processing market are Robert Bosch, EI Du Pont De Nemours and Company, Tetra Laval International, SPX Flow, IMA SpA, Becton Dickinson and Co, Amcor Limited, GEA Group, Greatview Aseptic Packaging Co, JBT Corporation, Sealed Air Corporation, SIG Combibloc Group, Schott AG, Shibuya Corporation, Powder Systems Limited, DS Smith PLC, Kwang Dah Enterprises, Mondi, and Elopak AS. Major players in the aseptic processing market are Robert Bosch, EI Du Pont De Nemours and Company, Tetra Laval International, SPX Flow, IMA SpA, Becton Dickinson and Co, Amcor Limited, GEA Group, Greatview Aseptic Packaging Co, JBT Corporation, Sealed Air Corporation, SIG Combibloc Group, Schott AG, Shibuya Corporation, Powder Systems Limited, DS Smith PLC, Kwang Dah Enterprises, Mondi, and Elopak AS.
Major players in the pharmacogenomics market are Abbott Laboratories, AstraZeneca plc, Becton Dickinson and Company, Bayer AG, F Hoffmann-La Roche AG, Illumina Inc, GlaxoSmithKline plc, Merck KGaA, Myriad Genetics Inc, Thermo Fisher Scientific Inc, OPKO Health Inc, Assurex Health Inc, Empire Genomics LLC, Future Science Group and Pathway Genomics Corporation. Major players in the pharmacogenomics market are Abbott Laboratories, AstraZeneca plc, Becton Dickinson and Company, Bayer AG, F Hoffmann-La Roche AG, Illumina Inc, GlaxoSmithKline plc, Merck KGaA, Myriad Genetics Inc, Thermo Fisher Scientific Inc, OPKO Health Inc, Assurex Health Inc, Empire Genomics LLC, Future Science Group and Pathway Genomics Corporation.
These days the most popular stocks to follow are either meme plays or the most blue-chip S&P 500 companies. Very few investors seem to be interested in hidden gem stock picks. About halfway through September, the index is down almost 15% year-to-date. Of the 11 sectors in the index, only energy (up 44.8% ) and utilities (up 7.5%) are up for the year. Of the 503 stocks in the index, 318 are down for the year. One possibility for finding hidden gem stock picks to beat the September slump is to limit your search to the companies in the index that are winning in 2022. However, of the 184 in positive territory, most are either energy or utilities-related, which makes sense given those two sectors are the clear winners this year. So, we need to go further afield to find three winners to bet on to beat the September slump. I’ll use three criteria to find my diamonds in the rough: 1) A constituent of the S&P SmallCap 600 or the S&P MidCap 400 , 2) Less than five analysts covering the company’s stock, and 3) An EBITDA (earnings before interest, taxes, and depreciation) margin of 20% or higher.
Becton, Dickinson and Company (BDX) said it launched a next-generation glass prefillable syringe ((PFS)) for vaccine PFS with tightened specifications for processability and contamination
Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc. , Abcam plc, Bio-Rad Laboratories, Inc. , PerkinElmer Inc. , Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc. Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc. , Abcam plc, Bio-Rad Laboratories, Inc. , PerkinElmer Inc. , Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc.
The Durable Medical Equipment Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Durable Medical Equipment Market report is to supply an
Embecta came in with a solid set of results that demonstrate its resiliency in a weakening economic outlook. Read why we rate EMBC stock a hold.
Becton, Dickinson and Co''s C.R. Bard Inc subsidiary must pay $4.8 million in a lawsuit brought by a Hawaii man who said he suffered serious complications after being implanted with the company''s hernia repair mesh, a Rhode Island jury found Monday.
A jury on Friday concluded that health equipment maker Becton, Dickinson (BDX) must award $4.8M as damages to a man who claimed that a hernia mesh sold by one of its units damaged…
Becton, Dickinson & Co convinced a Chicago federal judge on Monday that its system for moving hazardous drugs between syringes and drug vials does not infringe two patents owned by medical-device industry competitor Baxter International Inc.
Becton, Dickinson and Company (BDX) announced the consideration payable in connection with its tender offers to buy for cash up to $500M principal amount.The tender offer is for…
Becton, Dickinson and Company with ticker code (BDX) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 319 and 235 with a mean TP of 278.27. Now with the previous closing price of 263.71 this now indicates there is a potential upside of 5.5%. The day 50 moving average is 246.8 and the 200 day MA is 251.5. The company has a market capitalisation of $75,443m. You can visit the company''s website by visiting: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $79,608m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company''s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Related Stocks: HON , UNH , PXD , JCI , BDX ,
https://www.investing.com/news/pro/becton-dickinson-pt-raised-to-319-at-goldman-sachs-432SI-2873259
Related Stocks: FISV , XRAY , GLW , ROK , BDX ,
Becton Dickinson and Co (NYSE: BDX ) will sell Accelerate Diagnostics Inc''s (NASDAQ: AXDX ) rapid testing solution for antibiotic resistance and susceptibility, offering results in hours versus one to two days with some traditional laboratory methods. Becton Dickinson will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its global sales network. These solutions complement BD''s existing … Full story available on Benzinga.com
Becton, Dickinson and Company (BDX) signed an agreement to offer Accelerate Diagnostics'' (AXDX) rapid testing solution for antibiotic resistance and susceptibility.Under the agreement,…
PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company (“BD”), today reported financial results for the three and nine month periods ended June 30, 2022.
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” second quarter 2022 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy underperformed its Russell 1000 Value benchmark Index. The second quarter was highly volatile due to changes in interest rates, fears of recession, and […]
In trading on Tuesday, shares of Becton Dickinson and Company Depositary Shares E (Symbol: BDXB) crossed above their 200 day moving average of $52.02, changing hands as high as $52.16 per share. Becton Dickinson and Company Depositary Shares E shares are currently trading up a
In this article, we discuss the 5 healthcare stocks making moves after earnings. If you want to see some more healthcare companies moving on quarterly results, go directly to 10 Healthcare Stocks Making Moves After Earnings. 5. Becton, Dickinson and Company (NYSE:BDX) Number of Hedge Fund Holders: 49 Shares of Becton, Dickinson and Company (NYSE:BDX) […]
Becton, Dickinson and Company found using ticker (BDX) now have 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 290 and 235 calculating the average target price we see 273.18. Given that the stocks previous close was at 252.51 this would indicate that there is a potential upside of 8.2%. The 50 day MA is 245.32 and the 200 moving average now moves to 250.32. The market capitalisation for the company is $72,505m. Find out more information at: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $78,440m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Related Stocks: GILD , BDX , PFE , ALNY , ZBH ,
Becton Dickinson and Co (NYSE: BDX ) reported Q3 FY22 revenues of $4.6 billion , up 0.7% Y/Y (3.8% on a currency-neutral basis), better than the consensus of $4.47 billion. Revenue was driven by base revenue growth of 6% as reported, 9.3% currency-neutral. COVID-only testing revenues of $76 million declined from $300 million in the prior year. Medical … Full story available on Benzinga.com
Becton Dickinson and Co (NYSE:NYSE:BDX) Q3 2022 Earnings Conference Call August 04, 2022, 08:00 ET Company Participants Francesca DeMartino - SVP & Head, IR Thomas Polen - President,…
Shares of Becton, Dickinson (BDX), or BD, added as much as 4.7% to $256.41 in Thursday morning trading, after the medical device and health equipment maker reported Q3 results that…
Becton, Dickinson and Company is a dividend aristocrat that will become a dividend king soon. Read more to know why I think BDX stock is a Hold.
Becton Dickinson and Company (BDX)’s stock is trading at $244.14 at the moment marking a fall of -0.07% from the last session close. As of this writing, shares are priced at -11.95% less than their 52-week high of $277.29, and 6.50% over their 52-week low of $229.24. Based on the past 30-day period, the stock […]
Becton, Dickinson (NYSE: BDX ) has outperformed the market over the past 20 years by 3.42% on an annualized basis producing an average annual return of 11.36%. Currently, Becton, Dickinson has a market capitalization of $68.64 billion. Buying $1000 In BDX: If … Full story available on Benzinga.com
Becton, Dickinson (BDX) acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications, for providing customers with flexibility and capabilities in meeting…
We believe the healthcare sector''s strong growth momentum with average revenue growth of 3.8% QoQ suggests a positive outlook with the equipment industry forecasted at a market CAGR of 5.5%.
Becton, Dickinson (BDX) declares $0.87/share quarterly dividend, in line with previous.
Becton, Dickinson and Company found using ticker (BDX) have now 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 290 and 235 calculating the average target price we see 273.18. Now with the previous closing price of 241.08 this indicates there is a potential upside of 13.3%. There is a 50 day moving average of 246.65 and the 200 day moving average is 249.75. The market capitalisation for the company is $69,023m. Find out more information at: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $78,213m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Becton, Dickinson and Company with ticker code (BDX) have now 11 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 290 and 235 and has a mean target at 274.09. Given that the stocks previous close was at 234.16 this would indicate that there is a potential upside of 17.1%. The 50 day MA is 248.25 while the 200 day moving average is 249.77. The market cap for the company is $68,199m. Company Website: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $79,829m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company''s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
The following slide deck was published by Becton, Dickinson and Company in conjunction with this event.
Becton, Dickinson''s (NYSE: BDX ) short percent of float has fallen 31.36% since its last report. The company recently reported that it has 3.31 million shares sold short , which is 1.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.9 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Sleeping Pills Market 2022-2028 New Jersey, NJ -- ( SBWIRE ) -- 07/13/2022 -- 2022-2030 Report on Global Sleeping Pills Market by Player, Region, Type, Application and Sales Channel is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Global Sleeping Pills Market. Some of the key players profiled in the study are Abbott Laboratories, Actellon Pharmaceuticals, Allegiant Health, Ambitropin, Apotex, Aurobindo Pharma, Becton Dickinson, Cayman Chemical, GlaxoSmithKline, Hayao, Merck, Pfizer, Sanofi, Takeda Pharmaceutical & Teva Pharmaceuticals. Get free access to sample report @ https://www.htfmarketreport.com/sample-report/4097378-2022-2030-report-on-global-sleeping-pills-market Sleeping Pills Market Overview: The study provides comprehensive outlook vital to keep market knowledge up to date segmented by Hospital Pharmacy & Retail Pharmacy, , Zolpidem, Eszopiclone (Lunesta), Ramelteon (Rozerem), Ativan (Lorazepam) & Adapin (Doxepin) and 18+ countries across the globe along with insights on emerging & major players.
Baird cut Twitter, Inc. (NYSE: TWTR ) price target from $45 to $33. Twitter shares fell 5.4% to $34.81 in pre-market trading. Raymond James lowered HCA Healthcare, Inc. (NYSE: HCA ) price target from $245 to $220. HCA Healthcare shares fell 1.2% to close at $172.60 on Friday. Citigroup cut the price target on Becton, Dickinson and Company (NYSE: BDX ) from $265 to $235. Becton, Dickinson shares fell 2.4% to $239.62 in pre-market trading. Piper Sandler cut KKR & Co. Inc. (NYSE: Full story available on Benzinga.com
If history is any guide, there may be trouble ahead for shares of Becton, Dickinson (NYSE: BDX ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term … Full story available on Benzinga.com
PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report its financial results for the third quarter of fiscal year 2022 before the market opens on Monday, August 15, 2022.
Becton, Dickinson (BDX) announced on Thursday that its BD MAX Respiratory Viral Panel ((RVP)) — a combination test designed to detect multiple respiratory infections including COVID-19…
Becton, Dickinson''s (NYSE: BDX ) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 3.87 million shares sold short , which is 1.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Becton, Dickinson has been underperforming since a massive $24B deal for Bard in 2017. Why am I Neutral BDX stock recent bolt-ons? Click here to find out.
Becton, Dickinson and Company with ticker code (BDX) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 310 and 255 with a mean TP of 283.64. Given that the stocks previous close was at 242.54 this now indicates there is a potential upside of 16.9%. There is a 50 day moving average of 252.19 while the 200 day moving average is 250.27. The company has a market cap of $71,529m. Find out more information at: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $83,649m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company''s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for Progressive Corp (NYSE: PGR ) from Underperform to Market Perform. For the first quarter, Progressive had an EPS of $1.11, compared to year-ago quarter EPS of $1.73. The current stock performance of Progressive shows a 52-week-high of $121.36 and a 52-week-low of $89.35. Moreover, at the end of the last trading period, the closing price was at $109.75. According to Noble Capital Markets, the prior rating for Indonesia Energy Corp Ltd (AMEX: INDO ) was changed from Market Perform to Outperform. NoneAt the moment, the stock has a 52-week-high of $86.99 and a 52-week-low of $2.61. Indonesia Energy Corp closed at $6.85 at the end of the last trading period. For Middlesex Water Co (NASDAQ: MSEX ), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. In the first quarter, Middlesex Water showed an EPS of $0.68, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $121.42 and a 52-week-low of $75.77.
The shares of Becton, Dickinson (BDX) are trading higher in the pre-market Friday on low volume after Wells Fargo upgraded the health equipment maker to Overweight from Equal…
Becton, Dickinson and Company (BDX) on Wednesday said it was voluntarily recalling some of its intraosseous products due to some issues
- ← Previous
- 1
- 2
- 3
- 4
- 5
- 6
- Next →